{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:55:31Z","timestamp":1784120131014,"version":"3.55.0"},"reference-count":219,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body\u2019s own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors. We also discuss combining CRC vaccines with monoclonal antibodies, delve into preclinical studies of novel cancer vaccines, and assess the impact of these treatment methods on patient outcomes. This review seeks to provide a deeper understanding of the current state of CRC treatment by evaluating innovative treatments and their potential to redefine the prognosis of patients with CRC.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1350208","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T04:24:40Z","timestamp":1710217480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy"],"prefix":"10.3389","volume":"15","author":[{"given":"Salima","family":"Shebbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najat","family":"Binothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Darwaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan A.","family":"Niaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rwaa H.","family":"Abdulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamilah","family":"Borjac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar M.","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Bakur","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/pg.2018.81072","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.09.007","article-title":"Colorectal cancer immunotherapy: state of the art and future directions","volume":"2","author":"Cornista","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170111152436","article-title":"Colorectal cancer chemotherapy: the evolution of treatment and new approaches","volume":"24","author":"McQuade","year":"2017","journal-title":"Curr Med Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/jgo","article-title":"Immunotherapy in gastrointestinal cancers","volume":"8","author":"Grierson","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2018.73889","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1756284820917527","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9037217","DOI":"10.1155\/2020\/9037217","article-title":"Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions","volume":"2020","author":"Kreidieh","year":"2020","journal-title":"BioMed Res Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/vaccines8030371","article-title":"The landscape of tumor-specific antigens in colorectal cancer","volume":"8","author":"Rus Bakarurraini","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i48.5418","article-title":"Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens","volume":"24","author":"Wagner","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.942235","article-title":"Colorectal cancer vaccines: The current scenario and future prospects","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/vaccines9050535","article-title":"Evolution of cancer vaccines-challenges, achievements, and future directions","volume":"9","author":"Tay","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u201cbi-shRNAi(furin)\/GMCSF DNA\/autologous tumor cell\u201d vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120018224","article-title":"Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA","volume":"21","author":"Morse","year":"2003","journal-title":"Cancer Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769305","article-title":"Personalized immunotherapy in colorectal cancers: where do we stand","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093886","article-title":"Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients","volume":"9","author":"Gao","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2138","article-title":"A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival","volume":"16","author":"Barth","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318292919e","article-title":"A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer","volume":"258","author":"Morse","year":"2013","journal-title":"Ann Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines","volume":"112","author":"Morse","year":"2008","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0477-6","article-title":"Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers","volume":"57","author":"Toubaji","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1479-5876-12-55","article-title":"The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors","volume":"12","author":"Rahma","year":"2014","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2111","article-title":"Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy","volume":"11","author":"Gribben","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006774","article-title":"Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1\/2 clinical trial","volume":"11","author":"G\u00f6genur","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-019-0576-2","article-title":"Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients","volume":"7","author":"Snook","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"P444","DOI":"10.1186\/2051-1426-3-S2-P444","article-title":"Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients","volume":"3","author":"Morse","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3098","article-title":"First-in-man study of Ad-sig-hMUC1\/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers","volume":"36","author":"Tan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1038\/s41467-022-33834-4","article-title":"A phase I study of an adenoviral vector delivering a MUC1\/CD40-ligand fusion protein in patients with advanced adenocarcinoma","volume":"13","author":"Tan","year":"2022","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/vaccines9101201","article-title":"Case report: marked survival advantage of two colorectal cancer patients with liver metastases treated with vigil and FOLFOX-6","volume":"9","author":"Barve","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.015","article-title":"Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits","volume":"23","author":"Uyl-de Groot","year":"2005","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/pharmaceutics12020158","article-title":"Dendritic cell vaccines for cancer immunotherapy: the role of human conventional type 1 dendritic cells","volume":"12","author":"Calmeiro","year":"2020","journal-title":"Pharmaceutics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701777","article-title":"Personalized neoantigen-pulsed DC vaccines: advances in clinical applications","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7616","DOI":"10.1038\/s41598-023-34855-9","article-title":"Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer","volume":"13","author":"Aldilaijan","year":"2023","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/pharmaceutics15071969","article-title":"Cancer vaccines: from the state of the art to the most promising frontiers in the treatment of colorectal cancer","volume":"15","author":"Martinis","year":"2023","journal-title":"Pharmaceutics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13547","article-title":"Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer","volume":"109","author":"Kawamura","year":"2018","journal-title":"Cancer Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1479-5876-12-108","article-title":"A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)","volume":"12","author":"Hazama","year":"2014","journal-title":"J Transl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1479-5876-12-63","article-title":"A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome","volume":"12","author":"Hazama","year":"2014","journal-title":"J Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/vaccines9040390","article-title":"mRNA-based vaccines","volume":"9","author":"Kowalzik","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J BioMed Biotechnol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23803","article-title":"Trial watch","volume":"2","author":"Senovilla","year":"2013","journal-title":"OncoImmunology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","article-title":"DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy","volume":"165","author":"Tiptiri-Kourpeti","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2507","article-title":"Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunologic and clinical outcomes","volume":"22","author":"McCann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0283","article-title":"Multi-neoantigen vaccine drives predominately MHC class I CD8(+) T-cell responses, impacting tumor challenge","volume":"7","author":"Duperret","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines6040094","article-title":"Recombinant viruses for cancer therapy","volume":"6","author":"Chulpanova","year":"2018","journal-title":"Biomedicines"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biomedicines5010003","article-title":"Taking a stab at cancer; oncolytic virus-mediated anti-cancer vaccination strategies","volume":"5","author":"Aitken","year":"2017","journal-title":"Biomedicines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.707290","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1967444","article-title":"Association of influenza vaccine and risk of recurrence in patients undergoing curative surgery for colorectal cancer","volume":"60","author":"Gogenur","year":"2021","journal-title":"Acta Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904022116","article-title":"Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer","volume":"117","author":"Newman","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444539","article-title":"Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy","volume":"44","author":"Snook","year":"2014","journal-title":"Eur J Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1706-4","article-title":"Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer","volume":"64","author":"Balint","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e002374","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/biomedicines9010039","article-title":"Recent advances in monoclonal antibody therapy for colorectal cancers","volume":"9","author":"Hwang","year":"2021","journal-title":"Biomedicines"},{"key":"B70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12575-021-00147-7","article-title":"Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines","volume":"23","author":"Azadi","year":"2021","journal-title":"Biol Proced Online"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1237764","article-title":"Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i48","article-title":"Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B74","doi-asserted-by":"publisher","first-page":"109745","DOI":"10.1016\/j.biopha.2019.109745","article-title":"Advances of immune checkpoints in colorectal cancer treatment","volume":"123","author":"Jiao","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/cancers13040845","article-title":"Novel protein-based vaccine against self-antigen reduces the formation of sporadic colon adenomas in mice","volume":"13","author":"Belnoue","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729809","article-title":"Multi-epitope-based vaccines for colon cancer treatment and prevention","volume":"12","author":"Corulli","year":"2021","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.783527","article-title":"Identification of tumor antigens and design of mRNA vaccine for colorectal cancer based on the immune subtype","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1579","article-title":"Virus-like particles for vaccination against cancer","volume":"12","author":"Mohsen","year":"2020","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-017-0270-1","article-title":"Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer","volume":"5","author":"Donaldson","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1038\/s41467-021-25506-6","article-title":"A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity","volume":"12","author":"Das","year":"2021","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14049","article-title":"The role of exosomes on colorectal cancer: A review","volume":"33","author":"Ruiz-Lopez","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00521","article-title":"Revisiting the role of exosomes in colorectal cancer: where are we now","volume":"9","author":"Mannavola","year":"2019","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28080","article-title":"Tumor-derived exosomes: Potential biomarkers and therapeutic target in the treatment of colorectal cancer","volume":"234","author":"Mousavi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i31","article-title":"Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells","volume":"7","author":"Lugini","year":"2016","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1093607","article-title":"Exosomes as smart drug delivery vehicles for cancer immunotherapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04839-2","article-title":"Deciphering the immunopeptidome in vivo reveals new tumour antigens","volume":"607","author":"Jaeger","year":"2022","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","author":"Sermer","year":"2019","journal-title":"Hematol Oncol"},{"key":"B94","article-title":"Target selection of CAR T cell therapy in accordance with the TME for solid tumors","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","article-title":"Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells","volume":"10","author":"Qin","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00401","article-title":"Corrigendum: lymphocytes in cellular therapy: functional regulation of CAR T cells","volume":"10","author":"Dwivedi","year":"2019","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis Malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4034","article-title":"(IMC001) for the treatment of advanced GI cancers","volume":"41","author":"Luo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904137","article-title":"Recent advances in CAR-T cells therapy for colorectal cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.07.001","article-title":"HER2: An emerging target in colorectal cancer","volume":"42","author":"Greally","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/CJI.0000000000000251","article-title":"Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model","volume":"42","author":"Teng","year":"2019","journal-title":"J Immunother"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/cells12222590","article-title":"Circulating tumor cells as predictive and prognostic biomarkers in solid tumors","volume":"12","author":"Capuozzo","year":"2023","journal-title":"Cells"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.229","article-title":"Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer","volume":"30","author":"Zhang","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B115","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biology12020287","article-title":"CAR based immunotherapy of solid tumours-A clinically based review of target antigens","volume":"12","author":"Maher","year":"2023","journal-title":"Biol (Basel)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10350-004-6659-1","article-title":"Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases","volume":"46","author":"Sheen","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2361","article-title":"Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12","volume":"8","author":"Chi","year":"2019","journal-title":"Cancer Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001050","article-title":"Mucin expression in colorectal cancer (CRC): systematic review and meta-analysis","volume":"53","author":"Niv","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.5002.5002_5002_5012","article-title":"AC133, a novel marker for human hematopoietic stem and progenitor cells","volume":"90","author":"Yin","year":"1997","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i7.932","article-title":"Upregulated CD133 expression in tumorigenesis of colon cancer cells","volume":"17","author":"Yang","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2407-12-96","article-title":"Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker","volume":"12","author":"Schneider","year":"2012","journal-title":"BMC Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.176271","article-title":"High expression levels of putative hepatic stem\/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma","volume":"59","author":"Yang","year":"2010","journal-title":"Gut"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers Malignant potential by regulating metalloproteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J Hepatol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/scrt53","article-title":"Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia","volume":"2","author":"McGinley","year":"2011","journal-title":"Stem Cell Res Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/320232a0","article-title":"Transfer of specificity by murine \u03b1 and \u03b2 T-cell receptor genes","volume":"320","author":"Dembi\u0106","year":"1986","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.040","article-title":"T-cell-based immunotherapy in colorectal cancer","volume":"498","author":"Feng","year":"2021","journal-title":"Cancer Lett"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gov053","article-title":"Immune checkpoints and immunotherapy for colorectal cancer","volume":"3","author":"Singh","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-18-2022","article-title":"Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor","volume":"79","author":"Yokoyama","year":"2019","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","first-page":"8305","DOI":"10.3390\/ijms21218305","article-title":"Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies","volume":"21","author":"Hosseinkhani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676181","article-title":"The role of V-domain ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead","volume":"12","author":"Hosseinkhani","year":"2021","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2017.10.006","article-title":"Tumor cell-associated immune checkpoint molecules - Drivers of Malignancy and stemness","volume":"1868","author":"Marcucci","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: \u2018Beyond the T cell\u2019","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/cancers13102414","article-title":"Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine","volume":"13","author":"Derakhshani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12935-023-03157-5","article-title":"Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis","volume":"23","author":"Li","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B149","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43556-021-00038-z","article-title":"Targeting regulatory T cells for immunotherapy in melanoma","volume":"2","author":"Huang","year":"2021","journal-title":"Mol Biomed"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133679","article-title":"Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy","volume":"130","author":"Liu","year":"2020","journal-title":"J Clin Invest"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","article-title":"Immunogenicity of pembrolizumab in patients with advanced tumors","volume":"7","author":"van Vugt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02986-5","article-title":"A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186","volume":"70","author":"Herting","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2763","article-title":"A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer","volume":"9","author":"Yarchoan","year":"2020","journal-title":"Cancer Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur J Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002505","article-title":"Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects","volume":"9","author":"Suarez-Carmona","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin Epigenetics"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001427","article-title":"Efficacy and immune-related adverse event associations in avelumab-treated patients","volume":"8","author":"Kelly","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03283-5","article-title":"A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study","volume":"72","author":"Espanol-Rego","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001064","article-title":"Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study","volume":"8","author":"Verschraegen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B167","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-019-0508-1","article-title":"Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial","volume":"7","author":"Chung","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-018-0459-y","article-title":"Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial","volume":"7","author":"Keilholz","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00490","article-title":"A case report of sequential use of a yeast-CEA therapeutic cancer vaccine and anti-PD-L1 inhibitor in metastatic medullary thyroid cancer","volume":"11","author":"Del Rivero","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2018.102","article-title":"Nivolumab in renal cell carcinoma: current trends and future perspectives","volume":"5","author":"Ochoa","year":"2018","journal-title":"J Kidney Cancer VHL"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0696","article-title":"Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer","volume":"14","author":"Mehrvarz Sarshekeh","year":"2018","journal-title":"Future Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.08.001","article-title":"Current microsatellite instability testing in management of colorectal cancer","volume":"20","author":"Sun","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0308","article-title":"A TGFbeta-dependent stromal subset underlies immune checkpoint inhibitor efficacy in DNA mismatch repair-deficient\/microsatellite instability-high colorectal cancer","volume":"18","author":"Endo","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4161\/mabs.26436","article-title":"Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys","volume":"5","author":"Leabman","year":"2013","journal-title":"MAbs"},{"key":"B180","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.ctarc.2021.100405","article-title":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","volume":"28","author":"Calvo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02973-w","article-title":"First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"71","author":"Italiano","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B182","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B183","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/psp4.12880","article-title":"Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors","volume":"12","author":"Budha","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2051-1426-2-14","article-title":"Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer","volume":"2","author":"Raval","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B185","doi-asserted-by":"publisher","first-page":"103577","DOI":"10.1016\/j.drudis.2023.103577","article-title":"Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations","volume":"28","author":"Babar","year":"2023","journal-title":"Drug Discov Today"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: A review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1403694","article-title":"Product review on the Anti-PD-L1 antibody atezolizumab","volume":"14","author":"Shah","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: A randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Network Open"},{"key":"B189","doi-asserted-by":"publisher","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2093","article-title":"LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"32","author":"Weiss","year":"2021","journal-title":"Ann Oncol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","article-title":"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)","volume":"23","author":"Agarwal","year":"2022","journal-title":"Lancet Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2403","article-title":"Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2632-6","article-title":"MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach","volume":"144","author":"Schmoll","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S305466","article-title":"Immunotherapy for stage III NSCLC: durvalumab and beyond","volume":"12","author":"Fitzpatrick","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126582","article-title":"Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2018.1494575","article-title":"Durvalumab for the treatment of non-small cell lung cancer","volume":"12","author":"Mezquita","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33966","article-title":"Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high\/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer","volume":"150","author":"Oh","year":"2022","journal-title":"Int J Cancer"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0163","article-title":"Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases","volume":"27","author":"Kanikarla Marie","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B200","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.iotech.2022.100272","article-title":"160P COLUMBIA-1: A phase Ib\/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)","volume":"16","author":"Segal","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-2257","article-title":"Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9","volume":"79","author":"Lee","year":"2019","journal-title":"Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2474","article-title":"Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer","volume":"27","author":"Segal","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B204","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1634\/theoncologist.2019-0924","article-title":"A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005332","article-title":"Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"10","author":"Johnson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3017","article-title":"Phase I\/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000883","article-title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","volume":"8","author":"Taylor","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B208","article-title":"The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge","volume":"41","author":"Alexander","year":"2016","journal-title":"Pharm Ther"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: A phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001499","article-title":"RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study","volume":"8","author":"Cohen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O(6)-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Oncol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"101426","DOI":"10.1016\/j.tranon.2022.101426","article-title":"Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials","volume":"21","author":"Goel","year":"2022","journal-title":"Transl Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001302","article-title":"Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study","volume":"8","author":"Pakkala","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"key":"B216","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jim.2018.02.003","article-title":"Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction","volume":"456","author":"Bhagwat","year":"2018","journal-title":"J Immunol Methods"},{"key":"B217","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-019-0519-y","article-title":"Correction to: 33rd annual meeting & Pre-conference programs of the society for immunotherapy of cancer (SITC 2018)","volume":"7","author":"Berry","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3584","article-title":"A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"39","author":"Garralda","year":"2021","journal-title":"J Clin Oncol"},{"key":"B219","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT106","article-title":"Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic Malignancies: A Phase I\/II study2019","author":"Gregory","year":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1350208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T04:24:46Z","timestamp":1710217486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1350208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":219,"alternative-id":["10.3389\/fimmu.2024.1350208"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1350208","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"article-number":"1350208"}}